D. Jessica Jensen's Insider Trades & SAST Disclosures
D. Jessica Jensen's most recent trade in POINT Biopharma Global Inc was a trade of 461,250 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 27, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern D. Jessica Jensen.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| POINT Biopharma Global Inc | D. Jessica Jensen | EVP Clinical Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 461,250 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | D. Jensen Jessica | EVP Clinical Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 213,301 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | Jensen Jessica D. | EVP Clinical Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 136,055 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | Jessica Jensen D. | EVP Clinical Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 125,553 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | D. Jensen Jessica | EVP Clinical Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 13,766 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | Jessica D. Jensen | EVP Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2023 | 136,055 | 136,055 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | Jessica D. Jensen | EVP Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 13,766 | 13,766 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | Jessica D. Jensen | EVP Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2022 | 213,301 | 213,301 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | Jessica D. Jensen | EVP Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jul 2021 | 461,250 | 461,250 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges